Edition:
India

TESARO Inc (TSRO.OQ)

TSRO.OQ on NASDAQ Stock Exchange Global Select Market

27.57USD
14 Aug 2018
Change (% chg)

$0.41 (+1.51%)
Prev Close
$27.16
Open
$27.20
Day's High
$27.72
Day's Low
$27.20
Volume
166,540
Avg. Vol
522,943
52-wk High
$136.45
52-wk Low
$25.62

Chart for

About

TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.... (more)

Overall

Beta: 1.67
Market Cap(Mil.): $6,492.51
Shares Outstanding(Mil.): 54.18
Dividend: --
Yield (%): --

Financials

European shares enjoy timid rebound though trade war fears linger

LONDON European shares climbed on Wednesday but the modest rebound failed to erase the previous session's losses as investors' fears about an ongoing trade dispute between the United States and China lingered.

20 Jun 2018

UPDATE 2-European shares enjoy timid rebound though trade war fears linger

* France's CAC 40 underperforms as luxury stocks fall (Updates prices, adds details)

20 Jun 2018

BRIEF-Tesaro Reports Q1 Loss Per Share Of $2.98

* Q1 EARNINGS PER SHARE VIEW $-2.69 -- THOMSON REUTERS I/B/E/S

04 May 2018

BRIEF-Tesaro Announces Positive Top-Line Results From Quadra Trial Of Zejula

* TESARO ANNOUNCES POSITIVE TOP-LINE RESULTS FROM QUADRA TRIAL OF ZEJULA

24 Apr 2018

BRIEF-Tesaro Summarizes TSR-042 Clinical Data Presented At AACR

* TESARO INC - EXPECT TO COMPLETE ENROLLMENT IN MSI-H ENDOMETRIAL COHORT OF GARNET TRIAL BY END OF YEAR Source text for Eikon: Further company coverage:

16 Apr 2018

BRIEF-Tesaro And Medison Enter Into Exclusive Distribution Agreement To Commercialize Zejula In Israel

* TESARO AND MEDISON ENTER INTO EXCLUSIVE DISTRIBUTION AGREEMENT TO COMMERCIALIZE ZEJULA® IN ISRAEL

11 Apr 2018

BRIEF-Tesaro Says TOPACIO Data Demonstrates Compelling Clinical Activity Of Zejula In Patients With Type Of Ovarian Cancer

* DATA FROM TOPACIO TRIAL REPORTED AT SGO DEMONSTRATES COMPELLING CLINICAL ACTIVITY OF ZEJULA IN COMBINATION WITH AN ANTI-PD-1 ANTIBODY IN PATIENTS WITH PLATINUM RESISTANT/REFRACTORY OVARIAN CANCER

27 Mar 2018

BRIEF-Tesaro Inc Q4 Loss Per Share $3.35

* TESARO ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2017 OPERATING RESULTS

28 Feb 2018

BRIEF-Tesaro collaborates with Roche to evaluate their combination treatment for bladder cancer

* TESARO ANNOUNCES COLLABORATION TO EVALUATE COMBINATION OF ZEJULA® (NIRAPARIB) AND ANTI-PD-L1 CANCER IMMUNOTHERAPY IN METASTATIC BLADDER CANCER

27 Feb 2018

Earnings vs. Estimates